Fermenta Biotech Limited has submitted an application to the National Stock Exchange of India Limited (NSE) seeking approval for the listing and trading of its equity shares through a direct listing route. The application, filed on June 16, 2026, marks a significant step towards enhancing the accessibility of the company's securities for investors. This initiative follows an earlier intimation sent by the company to the exchange on May 26, 2026.

The direct listing route allows companies to list their shares without issuing new shares or raising fresh capital, providing an alternative path to public markets. By opting for this method, Fermenta Biotech aims to leverage the NSE platform to facilitate trading of its existing equity shares. The company's decision underscores its commitment to expanding its market reach and providing liquidity to its shareholders.

Application Details

The application process involves a formal submission to the NSE, outlining the company's intent and compliance with regulatory requirements. The key dates associated with this development are as follows:

The company's registered office is located in Thane, Maharashtra, and it operates under the corporate identity number L99999MH1951PLC008485. The application was signed by Varadvinayak Khambete, the Company Secretary & Head - Legal, on behalf of Fermenta Biotech Limited.

Strategic Implications

The move to list on the NSE is expected to provide Fermenta Biotech with greater visibility and access to a broader investor base. Direct listings are often perceived as a cost-effective alternative to traditional initial public offerings (IPOs), as they eliminate the need for underwriters and associated fees. This approach aligns with the company's strategy to optimize its capital structure while ensuring compliance with regulatory norms.

The approval from the NSE will enable the company's equity shares to be traded on one of India's premier stock exchanges, potentially enhancing shareholder value. The company has not disclosed any specific timeline for the completion of the listing process, but stakeholders can anticipate further updates as the application progresses.

Fermenta Biotech Limited will hold a group and one-to-one investor meeting in Mumbai on June 15, 2026, to discuss its audited financial results for the year ended March 31, 2026. The meeting, scheduled between 10:00 am to 06:00 pm, will be conducted in person through the company's Investor Relations firm, Kaptify Consulting. This interaction allows investors to engage directly with management regarding the FY26 performance.

The company confirmed that the investor presentation and the press release dated May 26, 2026, regarding the financial results have been uploaded on its website and the BSE Limited website. Fermenta Biotech stated that no unpublished price sensitive information (UPSI) will be shared during the meeting. The discussions will be based on publicly available information, and the schedule is subject to changes due to exigencies on the part of the company or investors.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Varadvinayak Khambete, Company Secretary & Head – Legal, signed the intimation on behalf of Fermenta Biotech Limited.